TB-500 Legal Status, FDA 503A Category, and Compounding Access

Access is under active FDA review — and may expand in 2026

TB-500 legal status, in one moving sentence: it is not an FDA-approved drug and sits in 503A Category 2 today, but its compounding eligibility is actively before the FDA's advisory process and may expand in 2026. The forward-looking fact first, because it is the live one. TB-500 — listed by FDA as "TB-500 (free base)" and "TB-500 acetate" — is individually named on the published agenda of the FDA Pharmacy Compounding Advisory Committee (PCAC) meeting scheduled for July 23–24, 2026, as a bulk drug substance "being considered for inclusion on the 503A Bulks List" ^[17]. The same agenda also lists BPC-157, KPV, and MOTs-C ^[17].

That is real momentum, and it is worth reading precisely. A scheduled PCAC discussion is an evaluation step — the committee considers whether a substance should be added to the list. It is not a listing decision, not a reclassification, and not a change in TB-500's current status ^[17]. The outcome of the meeting is not known, and nothing on this page assumes one. What is true today is that TB-500's compounding eligibility is actively before the FDA's advisory process, with a fragment-specific entry on the calendar — which is more than most research peptides can say.

The current fact: FDA 503A Category 2

As of today, FDA — which lists this substance as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" — has placed it in 503A "Category 2," the designation for bulk substances that may present significant safety risks ^[18]. The placement took effect with FDA's September 29, 2023 update to its list of nominated bulk drug substances, citing concerns including potential immunogenicity for certain routes of administration and a lack of important safety information ^[18].

Two consequences follow directly, both citable to FDA. First, as a Category 2 substance, TB-500 is not within FDA's enforcement-discretion policy for 503A compounding — the policy that, for Category 1 substances, lets compounders use a bulk substance while FDA continues its evaluation does not extend to Category 2 ^[18][19]. Second, TB-500 is not an FDA-approved drug; no New Drug Application or Biologics License Application has approved it as a finished medicine, and that approval question is separate from the compounding question ^[19].

FDA's own list entry also settles the identity: it names the substance as the LKKTETQ fragment associated with thymosin beta-4, describing the two together ^[18]. That is the regulatory record confirming what the science says — TB-500 is the fragment, and the parent protein is the thymosin beta-4 it is drawn from.

How the 503A and 503B framework works

Drug compounding in the U.S. runs on two sections of the Federal Food, Drug, and Cosmetic Act. Section 503A covers traditional, patient-specific compounding by state-licensed pharmacies and physicians, generally under a valid prescription for an individual patient. Section 503B covers FDA-registered "outsourcing facilities" that compound larger batches under cGMP-style oversight and FDA inspection ^[19].

A compounder may use a bulk drug substance — an active ingredient used as a starting material, rather than a finished approved drug — only if that substance has an applicable USP/NF monograph, is a component of an FDA-approved drug, or appears on FDA's 503A bulks list ^[19]. Substances not on a list are evaluated by FDA through a public nomination process, with input from the PCAC; being discussed by the committee is a step in that evaluation, not a final listing decision ^[19].

One further wrinkle dates the current categories. On January 7, 2025, FDA finalized a revised interim policy under which it no longer sorts newly nominated substances into these numbered categories; substances already in Category 1 may continue within the interim enforcement-discretion policy, while substances in Category 2 are not afforded that discretion even if their nominations are updated ^[19]. TB-500 sits in Category 2 under that framework today.

How legally compounded peptide access works

In general terms — and this is information about the landscape, not medical or legal advice, and not an offer to supply anything — a legally compounded medication is prepared only after an individual patient is evaluated by a licensed prescriber who determines a compounded preparation is appropriate and issues a valid, patient-specific prescription ^[19].

The preparation is then made by a state-licensed 503A compounding pharmacy (patient-specific) or, for larger office or batch use, sourced from an FDA-registered 503B outsourcing facility ^[19]. Telehealth can serve as the front-end channel through which the patient is evaluated and the prescription issued — but telehealth is a route to a licensed-prescriber consultation, not a separate legal status. It does not change which substances are eligible to be compounded, and it does not remove the need for a legitimate clinical evaluation and a valid prescription ^[19].

The ingredient-eligibility caveat is the one that matters for TB-500. A compounder may use a requested active ingredient only if it is eligible under the 503A/503B bulk-substance rules; ingredients FDA has flagged for significant safety risks are not eligible for routine 503A compounding while that status stands ^[19]. That is the present situation for TB-500 as a Category 2 substance — and it is the same situation the July 2026 PCAC discussion may, or may not, eventually revisit ^[17].

WADA-prohibited in sport

Independently of the FDA question, TB-500 is prohibited in sport. TB-500 and thymosin beta-4 fall under the World Anti-Doping Agency's prohibited peptide, growth-factor, and tissue-repair categories, and are banned both in and out of competition for the relevant classes ^[5]. They are detectable by LC-MS anti-doping assays, and a 2024 method specifically refined quantification of TB-500 and its metabolites for that purpose ^[15]. The compound has also been encountered as a designer drug in racehorses, which drove much of the equine and human detection work ^[5].

Is TB-500 legal?

TB-500 is sold by research suppliers for laboratory use and is not an FDA-approved drug ^[19]. FDA placed the LKKTETQ thymosin beta-4 fragment in 503A Category 2, so it is not within FDA's enforcement-discretion policy for routine 503A compounding ^[18]. It is also WADA-prohibited in sport ^[5]. This is general information, not legal advice.

Is TB-500 FDA approved?

No. TB-500 is not approved by the FDA for human use and has no approved therapeutic indication ^[19]. FDA has placed the LKKTETQ thymosin beta-4 fragment, listed as "also known as TB-500," in 503A Category 2 for compounding ^[18]. It is a research-chemical and veterinary-context substance, not a finished approved medicine.

What is the FDA 503A status of TB-500?

FDA lists the substance as "Thymosin beta-4, fragment (LKKTETQ), also known as TB-500" and placed it in 503A Category 2 — bulk substances that may present significant safety risks — effective with the September 29, 2023 update, citing immunogenicity and a lack of safety information ^[18]. It is named on the July 23–24, 2026 PCAC agenda as under consideration, a scheduled discussion, not a decision ^[17].

Can you get TB-500 from a compounding pharmacy?

As a Category 2 substance, TB-500 is not eligible for routine 503A compounding while that status stands, because FDA flagged it for significant safety risks ^[18][19]. Legally compounded access in general runs through a licensed-prescriber evaluation, a valid patient-specific prescription, and a 503A pharmacy or 503B facility — but only for eligible ingredients ^[19].

Is TB-500 banned by WADA and in competitive sports?

Yes. TB-500 and thymosin beta-4 fall under WADA-prohibited peptide, growth-factor, and tissue-repair categories and are banned in and out of competition ^[5]. They are detectable by LC-MS anti-doping assays, and a 2024 method specifically quantifies TB-500 and its metabolites for detection ^[15].